Coronavirus Update: Vir, WuXi Terminate COVID-19 Antibody Pact
Executive Summary
Xevudy, which was part of the deal, has already seen restrictions on its use due to diminished efficacy against Omicron. Plus, Ocugen is back in the game as the FDA has released the clinical hold on its Phase II/III vaccine trial, while Pfizer/BioNTech release new booster shot data for Comirnaty in children aged 6 months-5 years.
You may also be interested in...
Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
Pfizer/BioNTech Prepares COVID-19 Vaccine Booster For Children 5-11
Most children 5-11 in the US have not yet received a single vaccination, according to CDC.
US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant
The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2.